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Summary. Gastric cancer (GC) continues to be a highly 
aggressive malignancy with poor prognosis and low 
survival rates. The survival of patients with GC depends 
mainly on the stage of the disease, with early GC having 
a 5 year survival of 90-100% and advanced tumors a 5 
year survival of 15-25%. The role of other prognostic 
factors in these tumors is still under investigation. 28 
gastric dysplasia, 45 Early GC and 98 Advanced Gastric 
Cancers were evaluated for expression of the oncogenes 
p53, c-ErbB2, c-myc and the EGFr in paraffin-embedded 
material utilizing Avidin-Biotin immunohistochemistry 
techniques. In 34 cases of GC microvessel density 
(MVD) was determined in CD34 stained sections. 
Statistical correlations with stage, histologic type, 
differentiation degree, location, size, ploidy patterns and 
overall survival were done. The Mantel-Cox test was 
performed to evaluate which factors had an independent 
prognostic value. 
Both, tumor angiogenesis and p53 protein 
expression were statistically associated (95% confidence 
intervals) with overall survival in patients with GC. p53 
protein expression was also correlated with cardial 
location, nodal involvement and tumor stage. c-ErbB2 
may recognize a group of highly aggressive well 
differentiated adenocarcinomas with worse prognosis. 
c-myc was also significantly enhanced in well 
differentiated tumors. EGFr showed no significant 
associations. 
Mantel-Cox was performed to compare the 
prognostic value of tumor stage, p53 protein expression 
and tumor angiogenesis. Tumor angiogenesis was the 
most important prognostic indicator to predict overall 
survival in our series.  p53 expression was not 
independent and did not provide additional prognostic 
information to tumor stage. Our study suggests that 
angiogenesis as demonstrated by microvessel counts in 
CD34 stained sections is a significantly important 
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prognostic factor for predicting survival in gastric 
cancer. 
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Introduction 
Gastric cancer (GC) continues to be a highly 
aggressive malignancy with poor prognosis. Survival 
rates depend mainly on the stage of the disease when 
gastrectomy is performed. Patients with early gastric 
cancer have a 5 years survival of 90-100% while 
advanced gastric cancer have a 5 years survival of 15- 
25% (Ming and Goldman, 1992). However, further 
characterization of the prognosis of patients within these 
two groups is necessary in order to avoid excessive 
treatment, morbidity and costs. Immunohistochemical 
analyses of the expression of oncogenes, suppressor genes 
and growth factors have been proposed as prognostic 
indicators that routinely could be incorporated to 
diagnosis and may provide additional prognostic 
information to the histological evaluation of tumors. The 
expression of the p53 tumor suppressor gene, c-ErbB2 
and c-myc oncogenes, as well as the Epidermal Growth 
Factor receptor (EGFr) have been independently proposed 
to play a role in the prognosis of gastric cancer (Ninomiya 
et al., 1991; Martin et al., 1992; Sasano et al., 1992; Kiu 
et al., 1993; Motojima et al., 1994; Gabbert et al., 1995; 
Tokunaga et al., 1995). Recently, tumor angiogenesis has 
been found to be a predictor of recurrence and metastasis 
in GC (Maeda et al., 1995; Araya et al., 1997). 
Tumor cells require angiogenesis for nutritive supply. 
The newly formed vessels play an important role in tumor 
progression and metastatic dissemination (Weidner et al., 
1993). As shown by Liotta et al. (1974) a large number of 
tumor vessels increases the opportunity of the tumor cells 
to enter the circulation. Indeed, the newly formed 
capillaries usually have a fragmented basement 
membrane, making easier the possibility of invasion 
(Nagy et al., 1989). The putative role of angiogenesis in 




p53, C-ErbB2, c-myc and EGFr and prognosis in gastric carcinoma 
Counting microvessels  has proven to be 
reproducible though some discrepancies  in the 
prognostic value of this technique in certain tumors have 
been reported (Bosari et al., 1992). These discrepancies 
have been related to different sensitivity and specificity 
of the analyzed markers for endothelial cells. Prior 
studies of angiogenesis were performed with anti-FVIII, 
a marker for endothelial cells and megakaryocytes. 
Horak et al. (1993) reported CD31 to be a marker with 
higher sensitivity for endothelial cells than anti-FVIII 
marker, although occasionally mildly cross reactivity 
with plasma cells, fibroblast and tumor cells can be 
seen. CD34, a marker of hematopoietic progenitor cells 
and endothelial cells, has been also found to be more 
sensitive than anti-FVIII. However, mild crossreactivity 
has been also reported with fibroblasts and tumor cells. 
In our experience with this marker however, only 2 out 
of 28 cases showed mild fibroblast and tumoral cell 
positivity. 
The  present study shows that p53  expression 
correlates with overall survival. However, the prognostic 
significance of p53 expression depends on its association 
with tumor stage as demonstrated the Cox's proportional 
hazards model. This prognostic dependance has been 
already reported by others authors (Starzynska et al., 
1992; Motojima et al., 1994). c-ErbB2 may recognize a 
group of highly aggressive well differentiated 
adenocarcinomas as found by other groups (Motojima et 
al., 1994; Tokunaga et al., 1995). Both, p53 and c-ErbB2 
were associated with lymph node metastasis in early 
gastric cancer suggesting that a closer follow-up should 
be performed in that group of patients. c-myc and EGFr 
showed no remarkable association in this study with 
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gastric cancer prognosis. 
Angiogenesis as demonstrated by MVD in CD34 
stained sections is the most reliable immunohistological 
factor to correlate with prognosis in our series and does 
not depend on intestinal or diffuse histologic type, 
esophago-gastric junction or body-antrum location, the 
degree of differentiation or the tumor stage. 
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